Summary
Global Markets Direct’s, ‘Acute Heart Failure - Pipeline Review, H2 2016’, provides an overview of the Acute Heart Failure pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
- The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
- The report assesses Acute Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Heart Failure
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amgen Inc.
Capricor Therapeutics, Inc.
Eli Lilly and Company
Lee's Pharmaceutical Holdings Limited
Novartis AG
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Trevena, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Acute Heart Failure Overview 7
Therapeutics Development 8
Pipeline Products for Acute Heart Failure - Overview 8
Acute Heart Failure - Therapeutics under Development by Companies 9
Acute Heart Failure - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Acute Heart Failure - Products under Development by Companies 13
Acute Heart Failure - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Capricor Therapeutics, Inc. 15
Eli Lilly and Company 16
Lee's Pharmaceutical Holdings Limited 17
Novartis AG 18
Ono Pharmaceutical Co., Ltd. 19
PhaseBio Pharmaceuticals, Inc. 20
Trevena, Inc. 21
Acute Heart Failure - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
cenderitide - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
istaroxime - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
omecamtiv mecarbil MR - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ONO-4232 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
PB-1046 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ruboxistaurin - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
serelaxin - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
TRV-120023 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ularitide - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Acute Heart Failure - Dormant Projects 55
Acute Heart Failure - Discontinued Products 56
Acute Heart Failure - Product Development Milestones 57
Featured News & Press Releases 57
Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure 57
May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure 57
Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide 58
Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation 58
May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure 59
May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure 59
Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome 60
Mar 25, 2014: FDA Staff Says Novartis’ Serelaxin Shouldn’t Be Approved 60
Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion 61
Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU 62
Dec 02, 2013: Paladin Announces Filing of New Drug Submission for RLX030 (Serelaxin) 63
Sep 03, 2013: Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil 63
Sep 02, 2013: Novartis' serelaxin improved symptoms and mortality across multiple subgroups of patients with acute heart failure 65
Jun 21, 2013: Novartis's Serelaxin Receives FDA Breakthrough Therapy Designation For Acute Heart Failure 66
Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program 66
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70
List of Tables
Number of Products under Development for Acute Heart Failure, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Acute Heart Failure - Pipeline by Amgen Inc., H2 2016 14
Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016 15
Acute Heart Failure - Pipeline by Eli Lilly and Company, H2 2016 16
Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 17
Acute Heart Failure - Pipeline by Novartis AG, H2 2016 18
Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 19
Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 20
Acute Heart Failure - Pipeline by Trevena, Inc., H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Acute Heart Failure - Dormant Projects, H2 2016 55
Acute Heart Failure - Discontinued Products, H2 2016 56
List of Figures
Number of Products under Development for Acute Heart Failure, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Top 10 Targets, H2 2016 23
Number of Products by Stage and Top 10 Targets, H2 2016 23
Number of Products by Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29
